

IMPACT FACTOR 3.4





an Open Access Journal by MDPI

Cancer Biomarker Research and Personalized Medicine

Guest Editor:

Dr. James Meehan

The Royal (Dick) School of Veterinary Studies, Roslin Institute, The University of Edinburgh, Edinburgh, Midlothian, Scotland, UK

Deadline for manuscript submissions:

closed (15 January 2022)

Message from the Guest Editor

There is currently a major drive in oncology to achieve personalized cancer medicine through the identification and use of disease-specific biomarkers. These biomarkers include genes, intracellular or secreted proteins, circulating tumor cells, exosomes, and DNA. This Special Issue aims to describe current developments in biomarker research, outlining the latest advances in tissue- and blood/urine-based biomarker research.







IMPACT FACTOR 3.4





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous*))

Contact Us